Effects of the Intragastric Balloon MedSil® on Weight Loss, Fat Tissue, Lipid Metabolism, and Hormones Involved in Energy Balance
The prevalence of obesity continues to increase worldwide. Because obesity is associated with a number health-related problems as well as a shortened life span, treating obesity is an important clinical concern. Although various treatments are currently available, many are not efficacious in the long term. Therefore, additional medical treatment options for morbidly obese individuals must be explored. In this study, we examined the effects of the intragastric balloon MedSil® on anthropometric measures and hormones associated with lipid and energy metabolism.
Twenty-two obese patients underwent insertion of the intragastric balloon MedSil® following a clinical exam, body composition scan, and collection of blood samples. Six months following implantation of the balloon, additional anthropometric and serological measures were taken.
Six months following insertion of the MedSil® balloon, we observed significant decreases in body weight, body mass index, and fat mass. Compared with baseline levels, ghrelin serum levels were increased significantly, while leptin, FGF21, and glycated hemoglobin levels significantly decreased, 6 months after balloon insertion.
The MedSil® intragastric balloon is a safe and effective treatment for morbid obesity, with positive effects on anthropometric measures and lipid metabolism.
- Obesity and overweight, Factsheet N°311, 2011March [cited 2013 Jul 30]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html.
- Ackroyd, R, Mouiel, J, Chevallier, JM (2006) Cost-effectiveness and budget impact of obesity surgery in patients with type-2 diabetes in three European countries. Obes Surg 16: pp. 1488-1503 CrossRef
- Franz, MJ, VanWormer, JJ, Crain, AL (2007) Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 107: pp. 1755-1767 CrossRef
- Avenell, A, Brown, TJ, McGee, MA (2004) What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet 17: pp. 317-335 CrossRef
- Konopko-Zubrzycka, M, Baniukiewicz, A, Wróblewski, E (2009) The effect of intragastric balloon on plasma ghrelin, leptin, and adiponectin levels in patients with morbid obesity. J Clin Endocrinol Metab 94: pp. 1644-1649 CrossRef
- Pinheiro J, Bates D, DebRoy S, et al. (2013). nlme: Linear and nonlinear mixed effects models. R package version 3.1–109.
- R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.
- Genco, A, Cipriano, M, Bacci, V (2006) BioEnterics intragastric balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes (Lond). 30: pp. 129-133 CrossRef
- McFarland, RJ, Grundy, A, Gazet, JC (1987) The intragastric balloon: a novel idea proved ineffective. Br J Surg 74: pp. 137-139 CrossRef
- Giardiello, C, Borrelli, A, Silvestri, E (2012) Air-filled vs water-filled intragastric balloon: a prospective randomized study. Obes Surg 22: pp. 1916-1919 CrossRef
- Genco, A, Balducci, S, Bacci, V (2008) Intragastric balloon or diet alone? A retrospective evaluation. Obes Surg 18: pp. 989-992 CrossRef
- Imaz, I, Martínez-Cervell, C, García-Alvarez, EE (2008) Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg 18: pp. 841-846 CrossRef
- Dumonceau, JM (2008) Evidence-based review of the bioenterics intragastric balloon for weight loss. Obes Surg 18: pp. 1611-1617 CrossRef
- Crea, N, Pata, G, Della Casa, D (2009) Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg 19: pp. 1084-1088 CrossRef
- Sallet, JA, Marchesini, JB, Paiva, DS (2004) Brazilian multicenter study of the intragastric balloon. Obes Surg 14: pp. 991-998 CrossRef
- Evans, D, Scott, MH (2001) Intragastric balloon in the treatment of patients with morbid obesity. Br J Surg 88: pp. 1245-1248 CrossRef
- Lecumberri, E, Krekshi, W, Matía, P (2011) Effectiveness and safety of air-filled balloon Heliosphere BAG® in 82 consecutive obese patients. Obes Surg 21: pp. 1508-1512 CrossRef
- Dogan, UB, Gumurdulu, Y, Akin, MS (2013) Five percent weight lost in the first month of intragastric balloon treatment may be a predictor for long-term weight maintenance. Obes Surg 23: pp. 892-896 CrossRef
- Danielsen KK, Svendsen M, Mæhlum S, et al. Changes in body composition, cardiovascular disease risk factors, and eating behavior after an intensive lifestyle intervention with high volume of physical activity in severely obese subjects: a prospective clinical controlled trial. J Obes. 2013. doi: 10.1155/2013/325464. Epub 2013 Apr 22. PMID: 23710347; PMCID: PMC3654355.
- Weck, M, Bornstein, SR, Barthel, A (2012) Strategies for successful weight reduction—focus on energy balance. Dtsch Med Wochenschr 137: pp. 2223-2228 CrossRef
- Wycherley, TP, Brinkworth, GD, Clifton, PM (2012) Comparison of the effects of 52 weeks weight loss with either a high-protein or high-carbohydrate diet on body composition and cardiometabolic risk factors in overweight and obese males. Nutr Diabetes 2: pp. e40 CrossRef
- Sekino, Y, Imajo, K, Sakai, E (2011) Time-course of changes of visceral fat area, liver volume and liver fat area during intragastric balloon therapy in Japanese super-obese patients. Intern Med 50: pp. 2449-2455 CrossRef
- Mathus-Vliegen EM, Eichenberger RI. Fasting and Meal-Suppressed Ghrelin Levels Before and After Intragastric Balloons and Balloon-Induced Weight Loss. Obes Surg. 2013 Aug 6. [Epub ahead of print] PMID: 23918282.
- Martinez-Brocca, MA, Belda, O, Parejo, J (2007) Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg 17: pp. 649 CrossRef
- Klok, MD, Jakobsdottir, S, Drent, ML (2007) The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 8: pp. 21-34 CrossRef
- Sahu, A (2003) Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. Front Neuroendocrinol 24: pp. 225-253 CrossRef
- Kojima, M, Hosoda, H, Date, Y (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: pp. 656-660 CrossRef
- Cummings, DE, Purnell, JQ, Frayo, RS (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50: pp. 1714-1719 CrossRef
- Nikolic, M, Boban, M, Ljubicic, N (2011) Morbidly obese are ghrelin and leptin hyporesponders with lesser intragastric balloon treatment efficiency : ghrelin and leptin changes in relation to obesity treatment. Obes Surg 21: pp. 1597-1604 CrossRef
- Roubos, EW, Dahmen, M, Kozicz, T (2012) Leptin and the hypothalamo-pituitary-adrenal stress axis. Gen Comp Endocrino 177: pp. 28-36 CrossRef
- Belgardt BF, Brüning JC. CNS leptin and insulin action in the control of energy homeostasis. Ann N Y Acad Sci. 2010 Nov;1212:97–113. doi: 10.1111/j.1749-6632.2010.05799.x. Epub 2010 Nov 11. Review. PMID: 21070248.
- Mion, F, Gincul, R, Roman, S (2007) Tolerance and efficacy of an air-filled balloon in non-morbidly obese patients: results of a prospective multicenter study. Obes Surg 17: pp. 764 CrossRef
- Iglesias, P, Selgas, R, Romero, S (2012) Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol 167: pp. 301-309 CrossRef
- Reinehr, T, Woelfle, J, Wunsch, R (2012) Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab 97: pp. 2143-2150 CrossRef
- Zhang, X, Yeung, DC, Karpisek, M (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57: pp. 1246-1253 CrossRef
- Mraz, M, Bartlova, M, Lacinova, Z (2009) Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 71: pp. 369-375 CrossRef
- Mai, K, Schwarz, F, Bobbert, T (2011) Relation between fibroblast growth factor-21, adiposity, metabolism, and weight reduction. Metabolism 60: pp. 306-311 CrossRef
- Woelnerhanssen, B, Peterli, R, Steinert, RE (2011) Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy—a prospective randomized trial. Surg Obes Relat Dis 7: pp. 561-568 CrossRef
- Haluzíková, D, Lacinová, Z, Kaválková, P (2013) Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. Obesity (Silver Spring) 21: pp. 1335-1342 CrossRef
- Dastis, SN, François, E, Deviere, J (2009) Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy 41: pp. 575-580 CrossRef
- Effects of the Intragastric Balloon MedSil® on Weight Loss, Fat Tissue, Lipid Metabolism, and Hormones Involved in Energy Balance
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Volume 24, Issue 6 , pp 909-915
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Intragastric balloon
- Lipid metabolism
- Fat tissue
- Weight loss
- Industry Sectors
- Author Affiliations
- 1. Department of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava, 703 00, Czech Republic
- 2. Department of Clinical Studies, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava, 703 00, Czech Republic
- 3. Department of Surgical Studies, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava, 703 00, Czech Republic
- 4. Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava, 703 00, Czech Republic